Some metabolic benefits of SGLT2inhibitors are not limited to diabetics, but they also offer positive results innon-diabetic diseases, such as obesity, high blood pressure, or hyperuricemia.Other entities, such as hyperlipemia, PCOS or vascular aging need further studiesto corroborate the efficacy of SGLT2 inhibitors in patients without diabetesmellitus. This evidence concerns the gene SLC5A2 and obesity disorder.